Novel Targeted Therapies for Eosinophil-associated Diseases and Allergy

Overview

Journal Annu Rev Pharmacol Toxicol

Publisher Annual Reviews

Specialties Pharmacology
Toxicology

Date 2014 Oct 24

PMID 25340931

Citations 24

Authors

Susanne Radonjic-Hoesli

Peter Valent

Amy D Klion

Michael E Wechsler

Hans-Uwe Simon

Affiliations

Soon will be listed here.

Abstract

Eosinophil-associated diseases often present with life-threatening manifestations and/or chronic organ damage. Currently available therapeutic options are limited to a few drugs that often have to be prescribed on a lifelong basis to keep eosinophil counts under control. In the past 10 years, treatment options and outcomes in patients with clonal eosinophilic and other eosinophilic disorders have improved substantially. Several new targeted therapies have emerged, addressing different aspects of eosinophil expansion and inflammation. In this review, we discuss available and currently tested agents as well as new strategies and drug targets relevant to both primary and secondary eosinophilic diseases, including allergic disorders.

Citing Articles

Evidence of Inflammatory Network Disruption in Chronic Venous Disease: An Analysis of Circulating Cytokines and Chemokines.

Fraile-Martinez O, Garcia-Montero C, Gomez-Lahoz A, Sainz F, Bujan J, Barrena-Blazquez S Biomedicines. 2025; 13(1).

PMID: 39857734 PMC: 11763091. DOI: 10.3390/biomedicines13010150.

Childhood blood eosinophils and symptoms of allergic disorders: a cross-sectional study in Southern China.

Hou X, Luo W, Gan H, Chen T, Sun B Ann Med. 2022; 54(1):2929-2940.

PMID: 36259652 PMC: 9586638. DOI: 10.1080/07853890.2022.2134584.

Chronic Venous Disease during Pregnancy Causes a Systematic Increase in Maternal and Fetal Proinflammatory Markers.

Ortega M, Gomez-Lahoz A, Sanchez-Trujillo L, Fraile-Martinez O, Garcia-Montero C, Guijarro L Int J Mol Sci. 2022; 23(16).

PMID: 36012236 PMC: 9409364. DOI: 10.3390/ijms23168976.

Eosinophils in skin diseases.

Radonjic-Hoesli S, Bruggen M, Feldmeyer L, Simon H, Simon D Semin Immunopathol. 2021; 43(3):393-409.

PMID: 34097126 PMC: 8241748. DOI: 10.1007/s00281-021-00868-7.

Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.

Valent P, Degenfeld-Schonburg L, Sadovnik I, Horny H, Arock M, Simon H Semin Immunopathol. 2021; 43(3):423-438.

PMID: 34052871 PMC: 8164832. DOI: 10.1007/s00281-021-00863-y.

References

MacGlashan Jr D, Bochner B, Adelman D, Jardieu P, Togias A, McKenzie-White J . Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997; 158(3):1438-45. View

Slager R, Hawkins G, Ampleford E, Bowden A, Stevens L, Morton M . IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. J Allergy Clin Immunol. 2010; 126(4):875-8. PMC: 3772526. DOI: 10.1016/j.jaci.2010.08.001. View

Soumelis V, Reche P, Kanzler H, Yuan W, Edward G, Homey B . Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7):673-80. DOI: 10.1038/ni805. View

Nwajei F, Konopleva M . The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol. 2013; 2013:953982. PMC: 3556414. DOI: 10.1155/2013/953982. View

Chan M, Gigliotti N, Dotson A, Rosenwasser L . Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clin Transl Allergy. 2013; 3(1):29. PMC: 3875359. DOI: 10.1186/2045-7022-3-29. View

Huang M, Zhu J . The regulation of normal and leukemic hematopoietic stem cells by niches. Cancer Microenviron. 2012; 5(3):295-305. PMC: 3460044. DOI: 10.1007/s12307-012-0114-y. View

Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

von Gunten S, Vogel M, Schaub A, Stadler B, Miescher S, Crocker P . Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol. 2007; 119(4):1005-11. DOI: 10.1016/j.jaci.2007.01.023. View

Garrett J, Jameson S, Thomson B, Collins M, Wagoner L, Freese D . Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2003; 113(1):115-9. DOI: 10.1016/j.jaci.2003.10.049. View

10.

Gotlib J, Cools J . Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008; 22(11):1999-2010. DOI: 10.1038/leu.2008.287. View

11.

Stoeckle C, Simon H . CD8(+) T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases. Allergy. 2014; 68(12):1622-5. DOI: 10.1111/all.12311. View

12.

Remsing Rix L, Rix U, Colinge J, Hantschel O, Bennett K, Stranzl T . Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2008; 23(3):477-85. DOI: 10.1038/leu.2008.334. View

13.

Bose P, Park H, Al-Khafaji J, Grant S . Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leuk Res Rep. 2013; 2(1):18-20. PMC: 3747003. DOI: 10.1016/j.lrr.2013.02.001. View

14.

Spik I, Brenuchon C, Angeli V, Staumont D, Fleury S, Capron M . Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol. 2005; 174(6):3703-8. DOI: 10.4049/jimmunol.174.6.3703. View

15.

Fruehauf S . Current clinical indications for plerixafor. Transfus Med Hemother. 2014; 40(4):246-50. PMC: 3776405. DOI: 10.1159/000354229. View

16.

Burks A, Calderon M, Casale T, Cox L, Demoly P, Jutel M . Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013; 131(5):1288-96.e3. DOI: 10.1016/j.jaci.2013.01.049. View

17.

Herrmann K, Gross W, Moosig F . Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012; 30(1 Suppl 70):S62-5. View

18.

Rothenberg M, Klion A, Roufosse F, Kahn J, Weller P, Simon H . Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008; 358(12):1215-28. DOI: 10.1056/NEJMoa070812. View

19.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

20.

Salemi S, Yousefi S, Constantinescu M, Fey M, Simon H . Autophagy is required for self-renewal and differentiation of adult human stem cells. Cell Res. 2011; 22(2):432-5. PMC: 3271583. DOI: 10.1038/cr.2011.200. View